Walleye Capital
FLGT icon

Walleye Capital’s Fulgent Genetics FLGT Stock Holding History

Walleye Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,100
Closed -$38.8K – 4511
2024
Q4 		$38.8K Sell
2,100
-600
-22% -$11.7K ﹤0.01% 4411
2024
Q3 		$58.7K Sell
2,700
-3,900
-59% -$87.2K ﹤0.01% 4592
2024
Q2 		$129K Sell
6,600
-7,300
-53% -$152K ﹤0.01% 4580
2024
Q1 		$302K Buy
13,900
+4,400
+46% +$109K ﹤0.01% 3662
2023
Q4 		$275K Buy
+9,500
New +$254K ﹤0.01% 3439
2023
Q3 		– Sell
-7,000
Closed -$259K – 5012
2023
Q2 		$259K Buy
7,000
+5,300
+312% +$185K ﹤0.01% 2914
2023
Q1 		$53.1K Buy
+1,700
New +$54.7K ﹤0.01% 3190

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's FLGT Position: Q4 2025 in Review

Walleye Capital sold out of Fulgent Genetics (FLGT) in Q4 2025, closing a stake of 64,800 shares — an estimated $1.46M sold.

Walleye Capital first reported a position in FLGT in Q3 2022 and held it in 9 quarters. The position peaked at $1.46M in Q3 2025. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.

  • Walleye Capital reported no remaining Fulgent Genetics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 64,800 Fulgent Genetics shares in Q4 2025, an estimated $1.46M.
  • Walleye Capital first reported a position in Fulgent Genetics in Q3 2022 and held it in 9 quarters.
  • Walleye Capital's Fulgent Genetics position peaked at $1.46M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.